Background: Fluoropyrimidines are anticancer drugs used for the treatment of solid tumours. Apart from general side effects common to other anticancer drugs, the intravenously administered 5-fluorouracil (5-FU) and the recently developed oral prodrugs can induce toxicity at cardiovascular, neurologic and dermatologic level, which is reversed by treatment interruption, discontinuation, dose reduction and supportive therapies.
Objective: To examine, from the morphohistopathological point of view, the main toxic effects induced by fluoropyrimidines.
Methods: Pertinent articles were retrieved through PubMed search.
Results: Unlike dermatologic toxicity, with evident histopathological observations because of the easy approach to skin examination, cardio- and neurotoxicity are scarcely documented, with most imaging and functional data poorly altered. Animal models are useful to corroborate data obtained in humans. Fluoropyrimidines can associate with specific cutaneous side effects, including the hand-foot syndrome (HFS), with symmetrical erythema, dysaesthesia, dryness, rash, swelling and desquamation on palms and soles. Cardiotoxicity includes angina pectoris, arrhythmias, palpitation, hypotension, hypertension, malaise and dyspnea, until life-threatening damages, with myocardial infarction and sudden death. Neurotoxicity is an uncommon but potentially severe side effect, consisting of rare cases of cerebellar alterations with ataxia, as well as multifocal cerebral leukoencephalopathy, with or without seizures, announcing with dizziness, memory deficits, trismus, headache, vertigo, gait disturbances and confusion, until coma. These adverse events are likely due to direct chemotoxic effects of fluoropyrimidine metabolites and most of them can be regarded as allergic reactions triggered by the hapten-like properties of these molecules.
Conclusion: Fluoropyrimidines are able to induce specific morphohistopathological changes in tissues.
Keywords: Fluoropyrimidines, 5-fluorouracil, capecitabine, cardiotoxicity, neurotoxicity, hand-foot syndrome.
Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
Medicinal Chemistry Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy
Current HIV Research Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Adult-Onset Genetic Leukoencephalopathies. Focus on the More Recently Defined Forms
Current Molecular Medicine Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Modulatory Effect of Sinapic Acid in Toluene Induced Dementia of Leukoencephalopathy Type in Wistar Rats: a Biochemical Study
The Natural Products Journal The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Severe Preeclampsia
Current Women`s Health Reviews Novel Mutation of the NOTCH3 Gene in a Chinese Pedigree with CADASIL
CNS & Neurological Disorders - Drug Targets The Role of the Urokinase Receptor in Epilepsy, in Disorders of Language, Cognition, Communication and Behavior, and in the Central Nervous System
Current Pharmaceutical Design The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Current Drug Metabolism